JB Chemicals & Pharmaceuticals Limited announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results at a meeting held on January 16, 2026.

For the quarter ended December 31, 2025, the consolidated revenue from operations stood at ₹1064.72 crore (₹1,06,472 lakhs), with a net profit after tax of ₹207.82 crore (₹20,782 lakhs). The total comprehensive income after tax for the group was ₹207.50 crore (₹20,750 lakhs).

On a standalone basis, the revenue from operations for the same quarter was ₹990.91 crore (₹99,091 lakhs), and the net profit after tax was ₹179.27 crore (₹17,927 lakhs). The total comprehensive income after tax was ₹178.28 crore (₹17,828 lakhs).

For the nine months ended December 31, 2025, consolidated revenue from operations reached ₹3243.56 crore (₹3,24,356 lakhs), with a net profit after tax of ₹608.10 crore (₹6,0810 lakhs). Standalone revenue from operations for the nine-month period was ₹3053.46 crore (₹3,05,346 lakhs), and the net profit after tax was ₹577.56 crore (₹5,77,56 lakhs).

The company also noted that the statement of deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc., and the format for disclosing outstanding default on loans and debt securities, are not applicable for the quarter ended December 31, 2025.

Further, the company is undergoing a scheme of amalgamation with Torrent Pharmaceuticals Limited, following Torrent's acquisition of a significant stake. The Competition Commission of India has approved this acquisition, subject to modifications. The amalgamation, if approved, will result in Torrent issuing its equity shares to JB Chemicals shareholders at a pre-agreed swap ratio.